These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1981586)

  • 1. The use of enzyme-linked immunosorbent assays to study the plasma disposition of sheep polyclonal and rat monoclonal digoxin-specific Fab fragments in the rabbit.
    Timsina MP; Hewick DS
    J Pharm Pharmacol; 1990 Aug; 42(8):572-6. PubMed ID: 1981586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The plasma disposition of sheep antibody (Fab) fragments in the guinea-pig and rabbit.
    Timsina MP; Ostenfeld T; Hewick DS
    J Pharm Pharmacol; 1989 Nov; 41(11):786-8. PubMed ID: 2576050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of an enzyme-linked immunosorbent assay to study the disposition of sheep digoxin-specific immunoglobulin G and Fab fragments in the rat.
    Johnston PC; Stevenson IH; Hewick DS
    Clin Exp Immunol; 1988 Dec; 74(3):489-93. PubMed ID: 3233793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon.
    Smith TW; Lloyd BL; Spicer N; Haber E
    Clin Exp Immunol; 1979 Jun; 36(3):384-96. PubMed ID: 114346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The plasma kinetics of digoxin-specific Fab fragments and digoxin in the rabbit.
    Timsina MP; Hewick DS
    J Pharm Pharmacol; 1991 Nov; 43(11):807-10. PubMed ID: 1686913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a sensitive radioimmunoassay for Fab fragments: application to Fab pharmacokinetics in humans.
    Thanh-Barthet CV; Urtizberea M; Sabouraud AE; Cano NJ; Scherrmann JM
    Pharm Res; 1993 May; 10(5):692-6. PubMed ID: 8321833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The plasma disposition and renal elimination of digoxin-specific Fab fragments and digoxin in the rabbit.
    Timsina MP; Hewick DS
    J Pharm Pharmacol; 1992 Oct; 44(10):796-800. PubMed ID: 1360503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab.
    Grene-Lerouge NA; Bazin-Redureau MI; Debray M; Scherrmann JM
    Toxicol Appl Pharmacol; 1996 May; 138(1):84-9. PubMed ID: 8658517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity.
    Ujhelyi MR; Robert S
    Clin Pharmacokinet; 1995 Jun; 28(6):483-93. PubMed ID: 7656506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of digoxin-specific antibody fragments on digoxin disposition in the rat.
    Johnston PC; Stevenson IH; Hewick DS
    Biochem Pharmacol; 1987 Jul; 36(13):2215-20. PubMed ID: 3606637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fab-bound colchicine appears to adopt Fab fragment disposition in rats.
    Sabouraud AE; Urtizberea M; Benmoussa K; Cano NJ; Scherrmann JM
    J Pharm Pharmacol; 1992 Dec; 44(12):1015-9. PubMed ID: 1361548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication.
    Schaumann W; Kaufmann B; Neubert P; Smolarz A
    Eur J Clin Pharmacol; 1986; 30(5):527-33. PubMed ID: 3758140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colchicine-specific Fab fragments alter colchicine disposition in rabbits.
    Sabouraud AE; Urtizberea M; Cano NJ; Grandgeorge M; Rouzioux JM; Scherrmann JM
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1214-9. PubMed ID: 1545388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of digoxin immune Fab in patients with kidney failure.
    Ujhelyi MR; Robert S; Cummings DM; Colucci RD; Sailstad JM; Vlasses PH; Findlay JW; Zarowitz BJ
    Clin Pharmacol Ther; 1993 Oct; 54(4):388-94. PubMed ID: 8222481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and efficacy of digoxin specific Fab fragments in a child following massive digoxin overdose.
    Kearns GL; Moss MM; Clayton BD; Hewett DD
    J Clin Pharmacol; 1989 Oct; 29(10):901-8. PubMed ID: 2592582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digoxin-specific antibody fragments in the treatment of digoxin toxicity.
    Chan BS; Buckley NA
    Clin Toxicol (Phila); 2014; 52(8):824-36. PubMed ID: 25089630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin.
    Nguyen A; Reyes AE; Zhang M; McDonald P; Wong WL; Damico LA; Dennis MS
    Protein Eng Des Sel; 2006 Jul; 19(7):291-7. PubMed ID: 16621915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digoxin-specific Fab fragments impair renal function in the rat.
    Moran RJ; Struthers AD; Hewick DS
    J Pharm Pharmacol; 1994 Oct; 46(10):854-6. PubMed ID: 7699576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments.
    Ochs HR; Smith TW
    J Clin Invest; 1977 Dec; 60(6):1303-13. PubMed ID: 914999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age.
    Renard C; Grene-Lerouge N; Beau N; Baud F; Scherrmann JM
    Br J Clin Pharmacol; 1997 Aug; 44(2):135-8. PubMed ID: 9278197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.